| Unique ID issued by UMIN | UMIN000028537 |
|---|---|
| Receipt number | R000032662 |
| Scientific Title | The effect of newly somatostatin analogues for neuroendocrine tumor |
| Date of disclosure of the study information | 2017/08/31 |
| Last modified on | 2017/08/04 17:05:22 |
The effect of newly somatostatin analogues for neuroendocrine tumor
Medication for nueroendocrine tumor
The effect of newly somatostatin analogues for neuroendocrine tumor
Medication for nueroendocrine tumor
| Japan |
neuroendocrine tumor
| Endocrinology and Metabolism |
Malignancy
NO
Evaluation of neuroendocrine tumor shrinkage using newly somatostatin analogues.
Safety,Efficacy
To evaluate tumor shrinkage and hormon secretion from tumor after administration of newly somatostatin analogues.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
| Medicine |
pasireotide, 60mg/4weeks, 12 mo
| 20 | years-old | <= |
| Not applicable |
Male and Female
The patients who have endocrine tumor enlargement after administration of octreitide LAR.
non
10
| 1st name | |
| Middle name | |
| Last name | Itsuro ENDO |
Tokushima University Hospital
Endocrinology and Metabolism
3-18-15 Kuramoto-Cho, Tokushima City
088-633-7120
endoits@tokushima-u.ac.jp
| 1st name | |
| Middle name | |
| Last name | Itsuro ENDO |
Tokushima University Hospital
Endocrinology and Metabolism
3-18-15 Kuramoto-Cho, Tokushima City
088-633-7120
endoits@tokushima-u.ac.jp
Tokushima University
consigned research fund
Other
NO
| 2017 | Year | 08 | Month | 31 | Day |
Unpublished
Preinitiation
| 2017 | Year | 08 | Month | 31 | Day |
| 2017 | Year | 09 | Month | 01 | Day |
| 2017 | Year | 08 | Month | 04 | Day |
| 2017 | Year | 08 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032662